Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb) • iberdomide (CC-220) • Columvi (glofitamab-gxbm) • golcadomide (CC-99282)

3ms

Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 For Diffuse Large B-Cell Lymphoma. (PubMed, Blood Cancer Discov)

Golcadomide exhibited rapid, deep, and sustained degradation of transcription factors IKZF1 and IKZF3, surpassing the anti-tumor activity of the IMiD® agent lenalidomide in preclinical models. Pharmacological and CRISPR screening further revealed genes and pathways underlying golcadomide's antitumor efficacy. These findings supported golcadomide as a promising drug candidate for DLBCL, providing a strong rationale for future golcadomide-based regimens.

3 months ago

Journal

IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • IKZF3 (IKAROS Family Zinc Finger 3)

lenalidomide • golcadomide (CC-99282)

6ms

TOP-FLOR: Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. (clinicaltrials.gov)

P2, N=40, Active, not recruiting, Olivia Newton-John Cancer Research Institute | Recruiting --> Active, not recruiting

6 months ago

Enrollment closed

CD20 (Membrane Spanning 4-Domains A1)

CD20 positive • LDH elevation

Opdivo (nivolumab) • Rituxan (rituximab) • golcadomide (CC-99282)

6ms

FIL_RICCO: A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL) (clinicaltrials.gov)

P2, N=47, Recruiting, Fondazione Italiana Linfomi - ETS | Not yet recruiting --> Recruiting

6 months ago

Enrollment open

Rituxan (rituximab) • golcadomide (CC-99282)

6ms

Novel Cereblon-Binding Immunomodulators Have Increased Potency Against Gammaherpesvirus- Associated Lymphomas In Vitro. (PubMed, J Med Virol)

Cereblon-binding immunomodulators (CBIs), such as pomalidomide (Pom), show in vitro efficacy and clinical activity against certain of these lymphomas. Next generation CBIs, such as golcadomide (Golc) and iberdomide (Iber), have increased affinity to the primary cellular target, cereblon, making them potentially better anticancer agents...The novel CBIs had relatively little activity in Pom-resistant cell lines with low levels of cereblon, suggesting that binding to cereblon is also important for the functions of the novel CBIs. These data show that the newer CBIs are more potent and effective against PEL and BL lines than Pom, and therefore, are worth investigating clinically in patients with these tumors.

6 months ago

Preclinical • Journal

CRBN (Cereblon) • ICAM1 (Intercellular adhesion molecule 1) • IRF4 (Interferon regulatory factor 4) • CD86 (CD86 Molecule)

pomalidomide • iberdomide (CC-220) • golcadomide (CC-99282)

6ms

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4) (clinicaltrials.gov)

P3, N=400, Recruiting, Celgene | Not yet recruiting --> Recruiting

6 months ago

Enrollment open

Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • bendamustine • golcadomide (CC-99282)

6ms

CC-99282-NHL-001: A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) (clinicaltrials.gov)

P1/2, N=438, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting | Trial completion date: Apr 2027 --> Feb 2028 | Trial primary completion date: Apr 2026 --> Apr 2027

6 months ago

Enrollment closed • Trial completion date • Trial primary completion date

Rituxan (rituximab) • Gazyva (obinutuzumab) • Ezharmia (valemetostat) • Monjuvi (tafasitamab-cxix) • golcadomide (CC-99282)

7ms

EPCORE NHL-5: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma (clinicaltrials.gov)

P2, N=565, Recruiting, Genmab | Phase classification: P1/2 --> P2

7 months ago

Phase classification • Adverse events

BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)

Chr t(11;14)

Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • prednisone • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)